Description of Medical ServiceThe proposed medical service is an additional EGFR mutation test for the presence of the T790M mutation in patients with locally advanced (Stage IIIB) or metastatic (Stage IV), non-squamous or not otherwise specified EGFR mutation positive NSCLC, who have received first-line EGFR TKI treatment and whose disease has subsequently progressed.
Description of Medical ConditionLung cancer is the fourth most commonly diagnosed cancer in Australian men and women(1). Unfortunately, approximately 50% of patients with lung cancer are diagnosed when the disease is advanced and inoperable (2). Prognosis is poor with a 5-year survival rate of approximately 13% (3). In the past decade, targeted therapies for treatment of specific molecular subtypes of lung cancer have become available. There are approved and established therapies for patients with non-small cell lung cancer (NSCLC) known to have sensitising mutations of the Epidermal Growth Factor Receptor (EGFR) gene. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is not curative and the disease will ultimately progress in the majority of patients within 9-13 months (4).
Reason for ApplicationAmendment to MBS item
Medical Service TypeCo-dependent technology
Previous Application NumberNot Applicable
Final Protocol (PDF 1340 KB)
Final Protocol (Word 831 KB)
Public Summary DocumentPublic Summary Document - updated (PDF 891 KB)
Public Summary Document - updated (Word 89 KB)
Meetings for this Application
PASC13 - 14 August 2015
ESC5 October 2017
MSAC23 November 2017
22-23 November 2018